We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Essity Ab (publ) | LSE:0RQC | London | Ordinary Share | SE0009922156 | ESSITY ORD SHS CLASS A |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 224.75 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Med, Dental, Hosp Eq-whsl | 173.92B | 9.55B | 13.6030 | 1.74 | 16.59B |
From May 2019 to May 2024
STOCKHOLM, April 6, 2021 /PRNewswire/ -- The leading global hygiene and health company Essity is acquiring the distribution rights to the wound care technology Sorbact® in Australia and New Zealand from the Australian company Bayport Brands. In 2020, sales of Sorbact® in the region amounted to AUD 1.7m (approximately SEK 11m).
"This acquisition underlines our ambition to accelerate growth in advanced wound care, where we showed good organic sales growth during the second half of 2020. It is also a good fit for our strategy to establish a stronger presence in Australia and New Zealand, where we - in addition to our successful Medical Solutions operations - are also in the final phase of the acquisition of Asaleo Care," says Magnus Groth, President and CEO of Essity.
Sorbact® is a clinically established innovation for advanced wound care, which is manufactured and marketed by Abigo Medical. Essity acquired 75% of Abigo Medical in February 2020.
Sorbact® is used in wound care products to prevent and treat infections. It does this using a natural mode of action that binds bacteria and fungi. Sorbact® does not contain antiseptics or other toxic substances, which is positive for both the patient and the environment.
For further information, please contact:
Per Lorentz
Vice President Corporate Communications
+46 8 788 52 51
per.lorentz@essity.com
Johan Karlsson
Vice President Investor Relations
+46 8 788 51 30
johan.ir.karlsson@essity.com
This information was brought to you by Cision http://news.cision.com
https://news.cision.com/essity/r/essity-acquires-distribution-rights-to-sorbact-in-australia-and-new-zealand,c3319753
The following files are available for download:
https://mb.cision.com/Main/15798/3319753/1397182.pdf | Essity acquires distribution rights to Sorbact in Australia and New Zealand |
View original content:http://www.prnewswire.com/news-releases/essity-acquires-distribution-rights-to-sorbact-in-australia-and-new-zealand-301262606.html
SOURCE Essity
Copyright 2021 PR Newswire
1 Year Essity Ab (publ) Chart |
1 Month Essity Ab (publ) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
